Cumberland Pharmaceuticals (CPIX) Proxy filing summary

Executive summary

• Shareholders are asked to approve the sale of all FDA-approved commercial products and related assets to Apotex for $100 million in cash, with the company retaining its ifetroban product candidates and early-stage subsidiary CET.

• The board unanimously recommends voting in favor of the transaction, which is structured as an asset purchase and represents a strategic shift toward development-stage activities.

• The transaction is expected to close in Q2 or Q3 2026, subject to shareholder approval and other customary closing conditions.

• Proceeds will be used to maximize the value of retained programs and for working capital; no dividend distribution is currently planned.

Voting matters and shareholder proposals

• Proposal 1: Approve the sale of substantially all assets to Apotex as outlined in the Asset Purchase Agreement.

• Proposal 2: Authorize the board to adjourn/postpone the meeting if more time is needed to solicit proxies.

• Board recommends voting FOR both proposals.

• Voting and Support Agreements have been signed by directors and executives holding ~41% of shares, committing to vote in favor and not transfer shares.

Board of directors and corporate governance

• The board consists of seven members and formed a special committee to evaluate strategic alternatives and potential transactions.

• The board and special committee conducted a thorough review of alternatives, including negotiations with multiple parties, before unanimously approving the Apotex transaction.